| Literature DB >> 35411139 |
Huankun Fang1,2, Zhiqin Deng1, Jianquan Liu1, Siyu Chen3, Zhenhan Deng3, Wencui Li1.
Abstract
Senescence mainly manifests as a series of degenerative changes in the morphological structure and function of the body. Osteoporosis is a systemic bone metabolic disease characterized by destruction of bone microstructure, low bone mineral content, decreased bone strength, and increased brittleness and fracture susceptibility. Osteoblasts, osteoclasts and osteocytes are the main cellular components of bones. However, in the process of aging, due to various self or environmental factors, the body's function and metabolism are disordered, and osteoporosis will appear in the bones. Here, we summarize the mechanism of aging, and focus on the impact of aging on bone remodeling homeostasis, including the mechanism of ion channels on bone remodeling. Finally, we summarized the current clinical medications, targets and defects for the treatment of osteoporosis.Entities:
Keywords: aging; autophagy; bone formation; chlorine channel; epigenetics; osteoporosis
Mesh:
Year: 2022 PMID: 35411139 PMCID: PMC8994557 DOI: 10.2147/CIA.S349604
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Figure 1Mechanism of aging.
Figure 2Mechanism of SOP.
Common Clinical Medications and Limitations in the Treatment of Osteoporosis
| Name | Mechanism of Action | Target | Limitation | References |
|---|---|---|---|---|
| Raloxifene, tamoxifen | Binding to estrogen α or β receptors in osteoblasts and osteoclast, promoting osteoclast apoptosis and inhibit bone resorption | Estrogen receptor agonist | Increase the risk of breast cancer, endometrial cancer and deep vein thrombosis | [ |
| Teriparatide | Regulating calcium and phosphorus metabolism in vivo | Parathyroid hormone receptor agonist | Pain, vomiting, vertigo, hypercalcium in blood and hypercalcium in urine | [ |
| Calcium and vitamin D | Promoting the absorption and storage of Ca2+ in the body | Bone mineralization, and osteogenic differentiation | Kidney stones, hypercalcemia, myocardial infarction and other nonskeletal disorders | [ |
| Bisphosphonate | Inhibition of farnicic pyrophosphate synthase (FPPS) activity and osteoclast activity to inhibit bone resorption | Faricia pyrophosphate synthase inhibitor | Flu-like symptoms and bone or muscle pain, women with pregnancy needs should use them with caution or stop taking them before pregnancy | [ |
| Salmon calcitonin | Inhibit the differentiation of preosteoclasts into osteoclasts | Calcitonin receptor agonist | A potential cancer risk | [ |
| Simvastatin | Improving the high metabolic state of bone and alleviate bone loss. | Regulate lipid metabolism and promote bone formation | Liver insufficiency, muscle pain, inflammation, and rhabdomyolysis | [ |
| Monoclonal antibody drugs | Affecting the activity of osteoclasts and have positive effects on bone reconstruction and bone mineral density | Inhibit bone resorption | Osteonecrosis of the jaw | [ |